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The RNA-dependent RNA polymerase (RdRp) of SARS coronavirus (SARS-CoV) is essential for viral replication and a potential target
for anti-SARS drugs. We report here the cloning, expression, and purification of the N-terminal GST-fused SARS-CoV RdRp and its
polymerase catalytic domain in Escherichia coli. During purification, the full-length GST-RdRp was found to cleave into three main
fragments: an N-terminal p12 fragment, a middle p30 fragment, and a C-terminal p64 fragment comprising the catalytic domain, presumably
due to bacterial proteases. Biochemical assays show that the full-length GST-RdRp has RdRp activity and the p64 and p12 fragments form a
complex that exhibits comparable RdRp activity, whereas the GST-p64 protein has no activity, suggesting that the p12 domain is required for
polymerase activity possibly via involvement in template-primer binding. Nonnucleoside HIV-1 RT inhibitors are shown to have no evident
inhibitory effect on SARS-CoV RdRp activity. This work provides a basis for biochemical and structural studies of SARS-CoV RdRp and for
development of anti-SARS drugs.
D 2005 Elsevier Inc. All rights reserved.Keywords: SARS; Coronavirus; RNA-dependent RNA polymerase; PolymerizationIntroduction
Severe acute respiratory syndrome (SARS) is a new
acute respiratory infectious disease and the outbreak of
SARS in late 2002 in southeast China spread rapidly to over
30 countries and resulted in more than 800 deaths (Poutanen
et al., 2003; Tsang et al., 2003). The causative agent of0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Abbreviations: GST, glutathione S-transferase; MS, mass spectrometry;
MHV, mouse hepatitis virus; RdRp, RNA-dependent RNA polymerase;
SARS, severe acute respiratory syndrome; SARS-CoV, SARS coronavirus.
* Corresponding author. Fax: +1 86 21 54921116.
E-mail address: jpding@sibs.ac.cn (J. Ding).
1 These authors contributed equally to this work.SARS is a previously unidentified positive-strand RNA
virus that belongs to the Coronaviridae family, namely
SARS coronavirus (SARS-CoV) (Drosten et al., 2003;
Ksiazek et al., 2003; Peiris et al., 2003; Snijder et al.,
2003). Currently, there is neither vaccine nor effective
therapeutic treatments against this virus and a future
resurgence of SARS is possible. So far, the very limited
knowledge about SARS-CoV is mainly based on studies of
other coronaviruses, in particular mouse hepatitis virus
(MHV) which is very closely related to SARS-CoV (Navas-
Martin and Weiss, 2003). Coronaviruses are enveloped
RNA viruses with a single, positive-strand RNA genome
(Lai and Holmes, 2001). The viral genome of SARS-CoV
consists of about 29,727 nucleotides and encodes two large
replicase polyproteins expressed by two open reading05) 165 – 176
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ribosomal frameshift (Marra et al., 2003; Rota et al., 2003).
These polyproteins undergo co-translational proteolytic
processing by internal viral proteases into a set of mature
non-structural proteins that carry out multiple important
enzymatic functions during viral replication, including an
RNA-dependent RNA polymerase (RdRp), a 3C-like serine
proteinase (3CLpro), a papain-like proteinase (PL2pro), and
a superfamily 1-like helicase (HEL1) (Snijder et al., 2003).
In addition, the SARS-CoV genome also encodes a number
of structural proteins characteristic to coronaviruses, includ-
ing spike (S), envelope (E), membrane (M), nucleocapsid
(N), and short untranslated regions at both termini.
By analogy to other positive-strand RNA viruses,
SARS-CoV RdRp is predicted to be the central enzyme
that, together with other viral and cellular proteins,
constitutes a replication complex that is responsible for
replicating the viral RNA genome (Bost et al., 2000;
Brockway et al., 2003). The primary functions of the
replication complex are to transcribe the full-length
negative- and positive-strand RNAs, a 3V-coterminal set of
nested subgenomic mRNAs that have a common 5V
‘‘leader’’ sequence derived from the 5V end of the genome,
and the subgenomic negative-strand RNAs with common 5V
ends and leader complementary sequences at their 3V ends
(Lai and Holmes, 2001; Thiel et al., 2003). It has been
shown that the RNA replication activity takes place at
double-membrane vesicles in the host cell cytoplasm
(Gosert et al., 2002; Pedersen et al., 1999; Prentice et al.,
2004). Given its vital role in viral replication and the
success obtained with polymerase inhibitors in the treat-
ment of viral infections, SARS-CoV RdRp is an attractive
target for anti-SARS agents. However, currently, our
understanding about the biological functions of the RdRps
of SARS-CoV and other coronaviruses is very meager
because biochemical and structural studies of these
enzymes are hampered by the problem of expressing and
purifying a soluble and active protein. A modeling study of
the polymerase catalytic domain of SARS-CoV RdRp was
carried out based on sequence homology between SARS-
CoV RdRp and other viral polymerases and has identified
the conserved sequence motifs that are likely involved in
polymerization and predicted the typical right-hand top-
ology of the polymerase catalytic domain that consists of
fingers, palm, and thumb subdomains (Xu et al., 2003).
Most recently, immunoblotting and immunofluorescence
analyses using an antibody directed against a fragment of
SARS-CoV RdRp have detected a single protein with an
observed mass of 106 kDa in SARS-CoV infected Vero
cells, suggesting that a full-length SARS-CoV RdRp exists
in the life cycle of viral replication (Prentice et al., 2004).
In addition, an antibody generated against an MHV RdRp
fragment can also identify a full-length SARS-CoV RdRp
and several small proteins in SARS-CoV infected cell
lysates, demonstrating an epitope conservation between
MHV RdRp and SARS-CoV RdRp (Prentice et al., 2004).We report here the cloning, expression, and purification
of the full-length SARS-CoV RdRp and its polymerase
catalytic domain as glutathione S-transferase (GST) fusion
proteins. These recombinant proteins are characterized using
Western blot, N-terminal sequencing, mass spectrometry
(MS), and in vitro polymerase activity assay. The full-length
GST-RdRp exhibits good RdRp activity and weak RNA-
dependent DNA polymerase activity. During purification,
the full-length enzyme is found to be hydrolytically cleaved
into three main fragments: an N-terminal p12 fragment, a
middle p30 fragment, and a C-terminal p64 fragment which
comprises the polymerase catalytic domain. The cleavage
pattern was consistent and was presumably due to bacterial
proteases. The p64 and p12 fragments associate together to
form a tightly bound complex that possesses a comparable
RdRp activity, whereas the GST-p64 protein by itself has no
detectable activity, suggesting that the p12 domain is
required for the polymerase activity. Activity assays also
show that nonnucleoside inhibitors of HIV-1 RT cannot
inhibit the polymerase activity of SARS-CoV RdRp,
confirming our previous prediction that SARS-CoV RdRp
does not contain a hydrophobic pocket near the catalytic
active site (Xu et al., 2003). This work provides a basis for
further biochemical and structural studies of SARS-CoV
RdRp and for development of anti-SARS drugs.Results
Cloning, expression, and purification of SARS-CoV RdRp
SARS-CoV strain BJ101 was used to infect Vero cells
and the total viral RNA was extracted from the infected
cells. The cDNA complementary to the coding sequence of
SARS-CoV RdRp was obtained using reverse transcription
with random primers. Two overlapping DNA fragments
(R1, 1428 nucleotides and R2, 1458 nucleotides) that cover
the full-length SARS-CoV RdRp gene (2796 nucleotides)
were cloned separately and then ligated together. The full-
length RdRp (residues 1–932) has been successfully
expressed in Escherichia coli. as a GST-fusion protein with
a molecular mass of 132.8 kDa. Most of the recombinant
GST-RdRp protein was expressed in inclusion bodies and
found at the precipitated pellet of the cell lysate; a small
portion remained as soluble form in the supernatant. To
increase the quantity of the soluble protein, induction
experiments at different IPTG concentrations and temper-
atures were carried out. Change of the induction conditions
had very marginal effect (Fig. 1). High concentration of
IPTG appeared to yield a slightly higher expression level of
the soluble protein. It was also found that the expression
level of GST-RdRp in the Origami (DE3) cells was slightly
better than in the BL21 (DE3) (pLysS) cells (data not
shown). Therefore, the final protein expression experiments
were performed in the Origami (DE3) cells at the induction
condition of 1 mM IPTG and 28 -C for 3 h.
Fig. 1. Expression of SARS-CoV RdRp. (a) Supernatant of the cell lysates. (b) Pellet of the cell lysates. Protein expression was carried out in the Origami
(DE3) cells and induced at different IPTG concentrations and temperatures. Lanes 1–3: different IPTG concentrations of 0.1, 0.5, and 1 mM, respectively,
at 37 -C for 3 h; lane 4: molecular mass standards; lanes 5–7: different IPTG concentrations of 0.1, 0.5, and 1 mM, respectively, at 28 -C for 3 h; and
lanes 8–10: different IPTG concentrations of 0.1, 0.5, and 1 mM, respectively, at 24 -C for 3 h. The protein samples were analyzed in a 15% SDS-PAGE
gel stained with Coomassie blue.
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glutathione Sepharose 4B column. The purification yield
was low because most of the protein precipitated in inclusion
bodies and the protein had a poor binding affinity with the
column. Optimization of the purification procedure slightly
improved the yield which was typically about 0.2 mg GST-
RdRp protein with about 80% purity from 1 L of cell culture
(Fig. 2a). During purification, it was observed that the full-
length GST-RdRp protein was unstable and cleaved gradu-
ally when stored at both room temperature and 4 -C. Three
fragments with molecular masses of approximately 64 kDa
(p64), 39 kDa (p39), and 30 kDa (p30), respectively, are the
main products of the cleavage (Fig. 2b). Addition of the
protease inhibitor PMSF in the washing buffer did not
prevent the cleavage. To characterize the cleavage fragments,
the cleavage mixture of the full-length GST-RdRp protein
was further purified with the polyA Sepharose 4B column
(Fig. 2b). It is very interesting to find that the full-length GST-
RdRp protein bound poorly to the polyA column and most of
the protein went through the column. On the other hand,
majority of the p64 and p39 fragments bound to the column
andwere co-purified at amolar ratio of about 1:1; only a small
portion of them were in the flow-through fractions. The p30
fragment could not bind to the column and was found in the
flow-through fractions. The GST could not be completelyremoved by the polyA column purification due to its
abundance and existed as the main impurity in the purified
sample. Treatment of the protein sample with thrombin
cleaved the p39 fragment into two small fragments with
molecular masses of 12 kDa (p12) and 26 kDa, respectively,
while the p64 and p30 fragments remained intact. The 26-
kDa fragment was shown to be GST byWestern blot analysis.
Purification of the thrombin processed protein sample with
the polyA column showed that the p12 fragment also bound
to the column and was co-purified with the p64 fragment in
about 1:1 molar ratio (Fig. 3a). These results indicate that the
p64 and p12 (or p39) fragments appear to form a complex that
binds to polyA and the full-length GST-RdRp has a weaker
ability to bind to polyA than the p64/p12 complex. Formation
of a stable p64/p12 complex is also supported by results from
native PAGE and isoelectric focusing (IEF) gel analyses.
Native PAGE of the final protein sample exhibited a single
band corresponding to the p64/p12 complex and two bands
for GST (Fig. 3b). IEF gel of the protein sample also showed
that the p64/p12 complex migrated in a pH gradient as a
single bandwith a pI of about 5.2; GST had dual bands at pI of
5.3 and 5.4 (Fig. 3c).
The C-terminal p64 fragment of SARS-CoV RdRp
comprises the polymerase catalytic domain (see results
later). Attempts to chromatographically separate the p64 and
Fig. 3. Characterization of the p64/p12 complex. After purification with the
glutathione Sepharose 4B column, the full-length GST-RdRp protein
sample was stored at 4 -C for 5 days. One portion was treated with
thrombin for the cleavage of GST and another was not treated with
thrombin. Both samples were further purified with the polyA Sepharose 4B
column. (a) SDS-PAGE of the purified protein samples without (left panel)
and with thrombin treatment (right panel). (b) Native PAGE of GST (left
panel) and the purified protein sample with thrombin treatment (right
panel). (c) IEF gel of GST (left panel) and the purified protein sample with
thrombin treatment (right panel).
Fig. 2. Purification of SARS-CoV RdRp. (a) Purification of GST-RdRp with
the glutathione Sepharose 4B column. Lane 1: whole cell lysate without the
expression vector; lane 2: supernatant; lane 3: pellet; lane 4: elution fraction;
and lane 5: molecular mass standards. (b) Purification of GST-RdRp with
the polyA Sepharose 4B column. Lane 1: the cleavage mixture of the protein
sample after purification with the glutathione Sepharose 4B column in 5
days; lanes 2–4: flow-through fractions; lane 5: molecular mass standards;
and lanes 6–8: elution fractions. (c) Purification of GST-p64 with the
glutathione Sepharose 4B column. M: molecular mass standards; lane 1:
pellet; lane 2: flow-through fraction; and lane 3: elution fraction.
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biological property of the catalytic domain, we cloned the
recombinant p64 fragment separately that includes 563
residues from the C-terminus of the enzyme (residues 369–
932). Initial attempts of cloning this protein fragment
(termed p64) as a hexahistidine-tagged fusion protein (inthe pET22b+ or pET28b+ expression vector) resulted in
insoluble protein. Hence, p64 was subcloned in the pGEX-
4T1 expression vector and expressed in E. coli. strain BL21
Fig. 4. Western blot analysis of the cleavage mixture of the full-length GST-
RdRp. After purification with the glutathione Sepharose 4B column the
protein sample was stored at 4 -C for 5 days. (a) SDS-PAGE of the protein
sample. (b) Western blot of the protein sample. The gel shows that the full-
length GST-RdRp and the p39 fragment contain a GST tag while the p64
fragment does not.
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length GST-RdRp, most of the expressed GST-p64 protein
(molecular mass of 90.5 kDa) was insoluble (Fig. 2c). The
GST-p64 protein could not bind to the polyA Sepharose 4B
column. Therefore, purification of the GST-p64 protein was
carried out only with the glutathione Sepharose 4B column.
The purification effect was poor due to the weak binding of
the protein with the column and the purified GST-p64
protein was mixed with other small protein impurities. One
band with a molecular mass of 64 kD appears to be the GST-
cleaved p64 protein. This GST-p64 protein sample was used
in the polymerase activity assays.
Characterization of SARS-CoV RdRp
Characterization of the full-length GST-RdRp and of the
three cleavage fragments was carried out using Western blot,
mass spectrometry, and N-terminal sequencing analyses.
Western blot analysis showed that the full-length GST-RdRp
and the p39 fragment can be detected by anti-GST antibody,
while the p64 fragment cannot (Fig. 4). The p30 fragment
could not be detected by anti-GST antibody; however, sinceFig. 5. Schematic diagram showing the cleavage sites and compositions of the ful
comprises three domains. The N-terminal p12 domain consists of residues 1 to 110
p64 domain contains residues 369 to 932. The cleavage site between the p12 and p3
domains is at F368–K369. p64 comprises the polymerase catalytic domain which
that form the polymerase active site.this fragment was very close to GST (26 kDa) and the
Western blot band corresponding to GSTwas very broad due
to the excessive amount, this result is less certain. These
results indicate that both full-length GST-RdRp and the p39
fragment contain GST tag while the p64 fragment does not.
It can be deduced that the p39 fragment (and hence the p12
fragment) is located at the N-terminus of SARS-CoV RdRp,
while the p64 fragment is located in the middle or C-
terminus of the protein. To determine the locations of the p64
and p30 fragments in SARS-CoV RdRp, we carried out MS
analyses of these two fragments (data not shown). MS
spectra showed that the sequences of the peptides corre-
sponding to the base peaks of the p64 fragment can be
mapped to the C-terminal region of SARS-CoV RdRp and
those corresponding to the base peaks of the p30 fragment
match the middle part of SARS-CoV RdRp, suggesting that
p64 is located at the C-terminus and p30 in the middle of the
enzyme. However, it is noteworthy that some peptides
belonging to GST were also found in the base peaks with
relatively low abundance in the MS spectra of the p30
fragment probably due to contamination by the nearby GST
in sample preparation. To further identify the cleavage sites
of the protein fragments, we performed N-terminal sequenc-
ing of the p64 and p30 fragments. The first 5 amino acids of
the p64 fragment were determined to be KELLV which gives
a calculated molecular mass of 64.2 kDa for p64, consistent
with that determined by SDS-PAGE (64 kDa). The N-
terminal sequence of the p30 fragment was determined to be
VPHIS which gives a calculated mass of 29.9 kDa for p30, in
agreement with that determined by SDS-PAGE (30 kDa).
Taken together, we are able to map the location and
cleavage site of each fragment in SARS-CoV RdRp (Fig. 5).
The cleavage site between the p12 and p30 fragments is at
residues M110-V111 and the cleavage site between the p30
and p64 fragments is at residues F368–K369. The full-
length SARS-CoV RdRp consists of 932 amino acid
residues and has a molecular mass of 106.5 kDa and a
calculated pI of 5.995. p12 is located at the N-terminus and
consists of residues 1 to 110 (molecular mass 12.4 kDa and
calculated pI 5.835). p30 is located in the middle and spans
from residues 111 to 368 (molecular mass 29.9 kDa and
calculated pI 5.005). p64 is located at the C-terminus and
consists of residues 369 to 932 (molecular mass 64.2 kDa
and calculated pI 6.635) which comprise the polymerase
catalytic domain, as predicted in related molecular modeling
studies (Xu et al., 2003).l-length SARS-CoV RdRp. SARS-CoV RdRp consists of 932 residues and
; the middle p30 domain comprises residues 111 to 368, and the C-terminal
0 domains is at M110–V111 and the cleavage site between the p30 and p64
contains three strictly conserved aspartates (Asp618, Asp760, and Asp761)
Table 2
Effect of nonnucleoside HIV-1 RT inhibitors on activity of SARS-CoV
RdRp
Compound Incorporation
(cpm)
Relative
activity (%)
GST-RdRp (46.0 Ag/ml) 23,390 100
+a-APA R90384 (10 AM) 14,486 61.9
+HBY 097 (10 AM) 19,396 82.9
Reaction buffer control 310
Incorporation of [a-32P]UTP into the reaction with polyA/oligoU16 as the
template/primer. The GST-RdRp protein was purified with the glutathione
Sepharose 4B column.
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The RdRp activity of the full-length SARS-CoV RdRp
and of the cleaved fragments was examined using the filter-
binding polymerase assay. Specifically, we measured the
incorporation of [a-32P] UTP using polyA/oligoU16 as the
template/primer. The biochemical assays showed that the
RdRp activity of the cell lysate supernatant is weak (0.3
pmol/Ag/h) (Table 1). The full-length GST-RdRp purified
with the glutathione column had an easily measurable RdRp
activity (4 pmol/Ag/h or 13 folds of that of the lysate
supernatant). The full-length GST-RdRp was cleaved grad-
ually into three major fragments, p30, p39, and p64.
Proteolytic processing of this cleavage mixture with throm-
bin led to further proteolysis of p39 into GST and p12. The
RdRp activity of this mixture was 7.5 pmol/Ag/h or 24 folds
of that of the lysate supernatant. Purification of the thrombin-
treated protein sample with the polyA column yielded the
p64/p12 complex. This complex had a slightly higher RdRp
activity (10.9 pmol/Ag/h or 35 folds of that of the lysate
supernatant). The RdRp activity of the protein samples
processed with or without thrombin was not inhibited by
either rifampicin (20 Ag/ml) or actinomycin D (50 Ag/ml),
indicating that the measured RdRp activity is not caused by
contamination of bacterial RNA polymerase or DNA
polymerase. Compared to HCV RdRp, SARS-CoV RdRp
has a comparable RdRp activity (Yamashita et al., 1998).
Moreover, the full-length GST-RdRp protein also showed a
weak RNA-dependent DNA polymerase activity when using
polyrA/oligo(dT)12–18 as the template-primer (data not
shown). However, the recombinant polymerase catalyticTable 1
Summary of the RdRp activity of SARS-CoV RdRp
Concentration
(Ag/ml)
Incorporation
(cpm)
Specific activity
(pmol/Ag/h)
GST-RdRp
Sonication supernatant 54.6 962 0.3
Glutathione column
elution
120.6 27,357 4.0
Thrombin cleaved 149.8 64,519 7.5
PolyA column elution 138.8 86,487 10.9
+Rifampicin (20 Ag/ml) 138.8 59,394 7.5
+Actinomycin D
(50 Ag/ml)
138.8 83,091 10.5
GST-p64
Glutathione column elution 194.4 369 0.03
Reaction buffer control 284
Incorporation of [a-32P]UTP into the reaction with polyA/oligoU16 as the
template/primer. For the GSTP-RdRp, the protein samples were the
sonication supernatant, the full-length GST-RdRp after purification with
the glutathione Sepharose 4B column, the cleavage mixture of the full-
length GST-RdRp that was stored at 4 -C for 5 days and then processed
with thrombin for GST cleavage, and the p64/p12 complex after
purification with the polyA Sepharose 4B column. For the GST-p64, the
protein sample was only purified with the glutathione Sepharose 4B
column.domain (GST-p64) by itself had no measurable enzymatic
activity in the preliminary experiments (Table 1).
Molecular modeling studies of the polymerase catalytic
domain of SARS-CoV RdRp based on sequence compar-
ison of SARS-CoV RdRp with other viral polymerases
suggest that SARS-CoV RdRp lacks a hydrophobic pocket
near the polymerase active site that is observed in HIV-1
RT and is the binding site of nonnucleoside inhibitors (Xu
et al., 2003). To evaluate this prediction, we performed
polymerase activity assays of SARS-CoV RdRp in the
presence of two potent nonnucleoside HIV-1 RT inhibitors
(HBY 097 and a-APA R90384) (Kleim et al., 1999; Miller
et al., 1998). The results showed that these inhibitors
cannot inhibit the polymerase activity of SARS-CoV RdRp
which confirms our prediction based on the modeling
study (Table 2).Discussion
Like other positive-strand RNA viruses, SARS-CoV
RdRp is predicted to be part of a replication complex that
is responsible for the replication of viral RNA genome.
Currently, there is very limited knowledge about the
biological function(s) of this enzyme and other coronavirus
RdRps because of the lack of a soluble and active enzyme.
To pursue functional and structural studies of SARS-CoV
RdRp and understand the molecular basis of polymerization
and potential drug susceptibility of the enzyme, we have
cloned and expressed the full-length SARS-CoV RdRp and
a C-terminal fragment that contains the predicted polymer-
ase catalytic domain as fusion proteins with GST at the N-
terminus in E. coli. The expression and purification of the
proteins encountered difficulties. Most of the recombinant
full-length GST-RdRp was present in inclusion bodies and a
small portion existed as soluble form in supernatant.
Furthermore, the purified full-length GST-RdRp was unsta-
ble and hydrolytically cleaved to three main fragments,
presumably by bacterial proteases. The recombinant p64
domain was even more insoluble than the full-length GST-
RdRp with the vast majority of the protein expressed in
inclusion bodies. The full-length GST-RdRp was purified to
about 80% purity with an RdRp activity comparable to that
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the protein with the glutathione column, the purification
yield is low. The p64 protein was purified to a less
satisfactory purity and had no measurable polymerase
activity. This is the first report of successful expression
and purification of a soluble and active recombinant
coronavirus polymerase. The quality and quantity of the
purified proteins were sufficient good for preliminary
biochemical analysis which showed that SARS-CoV RdRp
is catalytically active in the absence of host factors.
However, further work will be needed to optimize the
expression and purification conditions to obtain large
quantity of homogeneous protein that is more suitable for
extensive biochemical and structural studies.
SARS-CoV RdRp has high contents of hydrophobic
residues (43.0% nonpolar and hydrophobic residues, 32.6%
of neutral and polar residues, 11.5% acidic residues, and
12.8% alkaline residues) and Cys residue (31 Cys or 3.32%
in the full-length RdRp and 16 Cys or 2.83% in the
polymerase catalytic domain), rendering it a hydrophobic
protein which may contribute in part to its poor solubility.
The poor solubility of SARS-CoV RdRp may be correlated
with its biological function(s) in infected cells. As a
characteristic feature of positive-strand RNA viruses, the
replication complex is associated with membranes in the
cytoplasm of host cells. Biochemical and biological data
have shown that MHV RdRp is associated with membranes
during cell lysis, centrifugation, and fractionation and that
MHV RdRp not only forms an important part of the
replication complex but is also involved in mediating its
efficient association with membrane, proteins, and RNA
(Brockway et al., 2003; Gosert et al., 2002; Pedersen et al.,
1999; Sims et al., 2000). This association would require
RdRp to interact with membrane proteins possibly and
preferably via hydrophobic interactions. Immunoblotting
and immunofluorescence analyses of SARS-CoV infected
cell lysates also showed that the replicase proteins of
SARS-CoV are co-localized to cytoplasmic complexes
containing markers for autophagosome membranes (Pren-
tice et al., 2004). Thus, it is possible that SARS-CoV RdRp
may play a similar role in the replication complex and
participates in interactions with membrane, proteins, and
RNA.
It is very intriguing to observe that during purification the
full-length SARS-CoV RdRp was unstable and was hydro-
lytically cleaved into three fragments, namely p12, p30, and
p64. The p64/p12 complex has comparable RdRp activity as
the full-length enzyme. The cause of the cleavage is unclear.
Whether these cleavages occur in the life cycle of viral
replication and whether the observed proteolytic cleavages
of the full-length enzyme have any biological implications
are also not clear. We explored the possibility of self
cleavage; however, sequence comparison of SARS-CoV
RdRp with known proteases did not reveal any potential
protease domain in SARS-CoV RdRp. At this point, it
appears that the observed proteolytic cleavages of the full-length SARS-CoV RdRp are not specific and are likely
caused by bacterial proteases, such as thermolysin and
subtilisin which have relatively broad cleavage specificity.
Since these cleavage sites are not typical proteolytic sites for
3CLpro (usually a conserved Gln at the P1 position) and
PL2pro (usually a conserved Gly at the P1 position) of
coronaviruses (Anand et al., 2003; Harcourt et al., 2004;
Kanjanahaluethai et al., 2003; Yang et al., 2003; Ziebuhr et
al., 1995) and there is no conserved residue motif in the
cleavage regions that is potential proteolytic site for 3CLpro
or PL2Pro, these two viral proteases are less likely to be
involved in the cleavages during the viral replication.
However, there are some cellular proteases such as elastase,
chymotrypsin, and trypsin that have relatively broad
substrate specificity. These cellular proteases might play
some roles in the cleavage of the full-length enzyme in the
virus-infected cells.
A full-length MHV RdRp (100 kDa) was detected as a
mature product in MHV infected cells by immonoprecipi-
tation experiments using antiserum against an N-terminal
peptide of MHV RdRp (Brockway et al., 2003). Immuno-
blotting and immunofluorescence analyses of SARS-CoV
infected cell lysates using an antibody directed against a
SARS-CoV RdRp fragment (which corresponds to approx-
imately residues 326-637 of SARS-CoV RdRp and covers
the C-terminal part of the p30 domain and the N-terminal
part of the p64 domain) detected a single protein with a
molecular mass of 106 kDa, corresponding to the full-length
SARS-CoV RdRp, in SARS-CoV infected Vero cells
(within 24 h after viral infection) (Prentice et al., 2004).
These results suggest that SARS-CoV RdRp appears to exist
as the full-length enzyme in the life cycle of viral
replication. However, immunoblotting experiments using
the antibody directed against the N-terminal of MHV RdRp
identified the full-length SARS-CoV RdRp as well as
several small proteins in SARS-CoV infected Vero cells
(Prentice et al., 2004). Moreover, since the sequences of the
cleavage sites are well conserved in RdRps of SARS and
group II coronaviruses (including MHV), it is possible that
these cleavages may also take place in other group II
coronavirus RdRps. Thus, we could not completely exclude
the possibility that the cleavage of the full-length SARS-
CoV RdRp may also occur in the viral life cycle and the
cleaved form of SARS-CoV RdRp may play some func-
tional role in the viral replication. Additional experiments
will be required to unequivocally determine the cause of the
cleavages and the functional form of the enzyme in the virus
infected cells.
The unusual high susceptibility of the full-length SARS-
CoV RdRp to proteolysis by bacterial proteases suggests
that the enzyme consists of multiple domains connected by
flexible regions that contain surface-exposed cleavage sites
to bacterial proteases. The flexibility of the enzyme might
be reduced when it interacts with other viral proteins and/or
factors from the infected cells. Our data suggest that SARS-
CoV RdRp appears to consist of three domains. The C-
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domain which is comparable in size to RdRps of other
positive-strand RNA viruses and is predicted to consist of
the fingers, palm, and thumb subdomains (Xu et al., 2003).
The N-terminal region of SARS-CoV and other coronavirus
RdRps is significantly large compared to RdRps of other
positive-strand RNA viruses and appears to consist of two
domains, p12 and p30, that have no equivalents in other
viral RdRps with known structures. The N-terminal p12
domain forms a complex with the p64 domain that bound
tightly to the polyA column. The p64/p12 complex is
catalytically active and has an RdRp activity comparable to
that of the full-length RdRp. The recombinant GST-p64
protein did not bind to the polyA column and had no
measurable polymerase activity. These results suggest that
the N-terminal p12 domain is required for optimal polymer-
ase activity of SARS-CoV RdRp, whereas the p30 domain
is dispensable for the catalytic reaction and has an unknown
function. Since both p64 and p12 domains contain
numerous Cys residues, the tight interaction between these
two domains suggests that disulfide bond(s) might be
involved in inter-domain interaction in addition to hydro-
phobic and hydrophilic contacts. The requirement of the
p12 domain for the binding of the p64 domain to the polyA
column and for the polymerase activity of the enzyme
suggests that the p12 domain is likely involved in
interaction with template-primer and/or stabilization of the
template-primer binding region of the enzyme. The RdRp
of reovirus (a double-strand RNA virus) comprises an N-
terminal domain (residues 1–380) that is comparable in size
to the N-terminal region of SARS-CoV RdRp. Crystal
structure of reovirus RdRp indicates that the N-terminal
domain flanks on one side of the nucleotide binding cleft
and forms part of a channel through which the incoming
nucleotide enters into the catalytic active site during
polymerization (Tao et al., 2002). The N-terminal region
of SARS-CoV RdRp might play a similar functional role as
that of reovirus RdRp. In addition, it is also possible that the
N-terminal domain(s) of SARS-CoV RdRp may be
involved in interactions with either other proteins from
the virus itself or host factors from the infected cells that
regulate or optimize the replication functions of SARS-CoV
RdRp.
Viral polymerases are essential for viral genome repli-
cation and are attractive targets for antiviral drug develop-
ment. Nonnucleoside inhibitors are a class of small organic
compounds of hydrophobic nature that have been known to
be potent and effective therapeutics with great specificity
against HIV-1. Similar inhibitors targeting HCV RdRp are
currently under development (Chan et al., 2003; Dhanak et
al., 2002; Love et al., 2003). These inhibitors act kinetically
in a non-competitive manner with respect to dNTP or rNTP
substrates. They either bind to a hydrophobic pocket close
to the polymerase active site in HIV-1 RT causing
conformational change of the polymerase active site and
restricting the flexibility of the nucleotide binding cleft (Daset al., 1996; Ding et al., 1995; Esnouf et al., 1995;
Kohlstaedt et al., 1992; Ren et al., 1995), or bind to a
hydrophobic pocket on the surface of the thumb subdomain
in HCV RdRp, interfering allosterically with conformational
change of the thumb (Love et al., 2003). Modeling studies
indicate that SARS-CoV RdRp contains neither a hydro-
phobic pocket near the polymerase active site nor an
inhibitor-binding pocket in the thumb subdomain. Thus, it
was predicted that nonnucleoside inhibitors which can
inhibit HIV-1 or HCV polymerase would not work for
SARS-CoV RdRp (Xu et al., 2003). Here, we showed that
two potent nonnucleoside HIV-1 RT inhibitors (a-APA
R90384 and HBY 097) exhibited no evident inhibitory
effect on the SARS-CoV RdRp activity. This information is
valuable in the development of anti-SARS drugs. We should
exclude these compounds that have similar chemical
structures and properties as nonnucleoside HIV-1 RT
inhibitors in the drug screening test. Nevertheless, alter-
native allosteric sites or surface pockets may exist in SARS-
CoV RdRp that could be potential targets for antiviral
agents. Detailed biochemical and structural studies of the
enzyme will likely reveal new inhibitor binding sites. Large-
scale drug screening might also identify new inhibitors of
SARS-CoV RdRp that could lead to the discovery of
potential inhibitor binding sites.
In summary, we present here a simple system for
expressing and purifying soluble and active SARS-CoV
RdRp in GST-fused form in E. coli. The availability of an
active recombinant SARS-CoV RdRp protein will not only
provide a tool for biochemical and structural studies of the
enzyme, but also facilitate efforts of antiviral drug develop-
ment. In addition, the active enzyme can also be used to
prepare both monoclonal and polyclonal antibodies against
SARS-CoV.Materials and methods
Construction of plasmids
Cultured Vero cells were infected with SARS-CoV BJ01
isolate (NCBI accession code: AY278488). The total viral
RNA was extracted from the infected cells with TRIZol
reagent (Invitrogen). The cDNA complementary to the
coding sequence of SARS-CoV RdRp (genome locations
13357. . .13383 and 13383. . .16151) was obtained by
reverse transcription using random primers. The two over-
lapping DNA fragments of RdRp (R1 and R2) were
amplified using primer sets RdRp1/RdRp1429r and
RdRp1338/RdRp2796r, respectively. The primers used are
RdRp1: 5V-GGGGCTCGAGCATGTCTGCGGATGCAT-
CAACGTTTTTAAAccGGGTTTGCGGTG -3V (the lower-
case letters indicate the site where the frameshift occurs
in the SARS-CoV genome); RdRp1429r: 5V-CAACAACTT-
CAACTACGAATAGGA-3V; RdRp1338: 5V-GGGGGGA-
TCCAACGCTGCTATCAGTGATTATG-3V; RdRp2796r:
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TGTA-3V; R11: 5V-GGATCCTCTGCGGATGCATCAACG-
3V; and R11r: 5V-CTACAGATAGAGACACCAGCTACG-3V.
R1 was further amplified using primers R11 (containing
a BamHI site) and R11r using Pryobest PCR Taq enzyme.
R2 was digested by EcoRVand HindIII and then cloned into
pBluescript KS(+) (Stratagene) to get pKSR2. The ampli-
fied R1 was digested by EcoRV and ligated into the EcoRV
site of pKSR2 to get pKSRdRp. pKSRdRp was then
digested by BamHI and XhoI and the RdRp gene was
subcloned into the pGEX-4T1 vector (Amersham Bioscien-
ces) to form the pGEX-4T1-RdRp construct. At the 5V-end
of the RdRp gene, a sequence encoding the GST protein was
attached. The open reading frame of the final construct and
the encoding of SARS-CoV RdRp (residues 1–932) were
confirmed by DNA sequencing.
A 1.7-kb DNA fragment corresponding to the polymerase
catalytic domain of SARS-CoV RdRp (p64, residues 369–
932) was amplified from the pGEX-4T1-RdRp construct by
using primers S1 (5V-ATCGGGATCCAAGGAACTTT-
TAGTGTATGCTGC-3V) and S1r (5V-ATCGCTCGAGT-
CACTGCAAGACTGTATGTGGTGT-3V). S1 contains a
BamHI site and S1r contains an XhoI site. The DNA
fragment was digested by these two enzymes and the p64
gene was subcloned into the pGEX-4T1 vector to form the
pGEX-4T1-p64 construct. The sequence encoding the GST
tag was inserted at the 5V-end of the p64 gene. The pGEX-
4T1-p64 construct was also verified by DNA sequencing.
Expression and purification of the full-length SARS-CoV
RdRp
The pGEX-4T1-RdRp plasmid was transformed in two
E. coli strains: Origami (DE3) (Novagen) and BL21 (DE3)
(pLysS) (Novagen). A single colony was grown at 37 -C for
12 h in 15 mL of 2 YT medium supplemented with
ampicillin (0.1 mg/ml). The cell culture was further grown
at 37 -C in 1 L of 2  YTG medium containing ampicillin
(0.1 mg/ml) until OD600 reached 0.8–1.0. Protein expres-
sion was induced with 0.5 mM IPTG at 28 -C for 3 h and
the cells were harvested by centrifugation at 7000  g and
4 -C for 20 min and washed with a PBS buffer.
Protein purification was carried out using affinity
chromatography with the glutathione Sepharose 4B and
polyA Sepharose 4B columns (Amersham Biosciences).
The cell pellet was resuspended in buffer A (4.3 mM
Na2HPO4, 1.5 mM KH2PO4, pH 7.3, 0.14 M NaCl, and 2.7
mM KCl) containing 1 mM PMSF and lysed on ice by
sonication. The lysate was centrifuged at 14,000  g and
4 -C for 30 min. After being filtered through a 0.45 Am
micron membrane, the supernatant was loaded onto a
glutathione Sepharose 4B column equilibrated with the
washing buffer. The column was washed with the buffer
until no protein was detected in the flow-through solution.
The bound protein was then eluted with 4 column volumes
of buffer B (10 mM reduced glutathione, 50 mM Tris–HCl,and pH 8.0). The elution fractions were pooled and dialyzed
against buffer C (20 mM Tris–HCl, pH 8.0, 10% glycerol, 1
mM EDTA, and 1 mM DTT) for 24 h.
The purified full-length GST-RdRp was found to be
cleaved gradually into three main fragments with apparent
molecular masses of 30 kDa (p30), 39 kDa (p39), and 64
kDa (p64), respectively. Later experiments showed that the
p39 fragment can be further proteolyzed using thrombin into
two small fragments: a 26-kDa GST and a 12-kDa fragment
(p12). To separate and characterize these cleavage frag-
ments, the protein solution was applied onto a polyA
Sepharose 4B column equilibrated with buffer C. After
washing with buffer C several times, the target proteins were
eluted with a linear gradient of 0–1 M NaCl in buffer C.
SDS-PAGE analyses were performed to check the purity
and quality of the protein samples at every stage of
purification. The purified proteins were characterized by
Western blot, mass spectrometry, N-terminal sequencing,
and polymerase activity assay.
Expression and purification of the catalytic domain of
SARS-CoV RdRp
The expression and purification of the polymerase
catalytic domain (p64) were similar to those for the full-
length RdRp. The pGEX-4T1-p64 plasmid was expressed in
E. coli strain BL21 (DE3) (pLysS). A single colony was
grown overnight at 30 -C in 20 mL of 2  YTG medium in
the presence of ampicillin and chloramphenicol (0.1 mg/ml).
The cell culture was used to inoculate 1 L of 2  YTG
medium containing ampicillin (0.1 mg/ml) and grown to an
OD600 of 1.0 at 30 -C. Protein expression was induced
overnight with 0.1 mM IPTG at 20 -C. The cells were
harvested by centrifugation at 6000  g and 4 -C for 10 min
and washed with a PBS buffer.
The cell pellet was resuspended in buffer A containing
1 mM PMSF and lysed on ice by sonication. The lysate was
centrifuged at 18,000  g and 4 -C for 30 min. The
supernatant was immediately applied onto a glutathione
Sepharose 4B column equilibrated with buffer A and the
column was washed with the same buffer until no protein
was detected in the flow-through solution. The bound
proteins were eluted with 4 column volumes of buffer B and
the elution fractions were pooled and dialyzed against buffer
C for 24 h. Further purification with a polyA Sepharose 4B
column was unsuccessful because the p64 protein could not
bind to the column. Therefore, the protein sample purified
with the glutathione Sepharose 4B column was used in the
polymerase activity assays.
Western blot analysis
During purification, the full-length GST-RdRp was found
to be proteolytically cleaved into three main fragments, p30,
p39, and p64. To identify which fragment is located at the
N-terminus of GST-RdRp, we performed Western blot
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purified with the glutathione Sepharose 4B column was
stored at 4 -C for 5 days to allow proteolysis of sufficient
portion of GST-RdRp. The cleaved protein fragments were
separated with a 12% SDS-PAGE gel and transferred into a
PVDF film (0.2 Am, Bio-Rad) using Bio-Rad Mini Trans-
Blot Cell. The PVDF film was washed with TTBS, blocked
with 5% milk-TTBS, and further washed with TTBS. The
PVDF film was then incubated with an anti-GST antibody
(Amersham Pharmacia, 1:200 dilution) at 4 -C for over-
night. After another washing with TTBS, it was incubated
with mouse anti-rabbit antibody coupled with AP (Amer-
sham Pharmacia, 1:5000 dilution) at room temperature for
60 min and then washed again with TTBS. Bands were
detected with a BCIP/NBT coloration kit (SABC). The host
strain BL21 (DE3) (pLysS) was used as a negative control.
Mass spectrometry analysis
To identify the locations of the p64 and p30 fragments in
the full-length GST-RdRp and their molecular masses, we
carried out mass spectrometry analyses of these fragments.
After purification with the glutathione Sepharose 4B
column, the protein sample was allowed to store at 4 -C
for 5 days and then separated with SDS-PAGE. The stained
protein bands corresponding to the p64 and p30 fragments
were excised from the gel and digested with trypsin
(Zeng et al., 2003). Specifically, the gel slices were des-
tained in a solution containing 30% acetonitrile and 100 mM
NH4HCO3 for 20 min and then dried in vacuum. 10 AL of
40 mM NH4HCO3 containing trypsin (the ratio of sample to
trypsin is about 40) (sequencing grade, Promega) was added
in the gel and incubated at 4 -C for 1 h, and then additional
40 mM NH4HCO3 solution was added to cover gel pieces.
Tube was sealed and incubated at 37 -C for 22 h. These
samples were further prepared using a reverse phase HPLC
and a C18 column (120 Am  150 mm, Thermo Hypersil-
Keystone) on a surveyor LC system (Thermo Finnigan). MS
data were acquired on an LTQ linear ion trap mass
spectrometer (Thermo Finnigan) equipped with an electro-
spray interface and operated in positive ion mode. The
acquired MS spectra were automatically searched against
protein databases for SARS-CoV, Schistosoma, and E. coli
using the TurboSEQUEST program in the BioWorksi 3.0
software suite. An accepted SEQUEST result had a DCn
score of at least 0.1 (regardless of charge state). Peptides
with a +1 charge state were accepted if they were fully
tryptic and had a cross correlation (Xcorr) >1.9. Peptides
with a +2 charge state were accepted if they had an Xcorr
>2.5 and peptides with a +3 charge state were accepted if
they had an Xcorr >3.7.
N-terminal sequencing
To determine the cleavage sites, we performed amino
acid sequencing of the N-termini of the p64 and p30fragments. After purification with a glutathione Sepharose
4B column the protein sample was stored at 4 -C for 5 days.
To prepare the p30 fragment, a fraction of the protein
mixture was separated with SDS-PAGE and the protein
band corresponding to p30 was cut from the gel for further
analysis. To prepare the p64 sample, a fraction of the protein
mixture was first subjected to thrombin cleavage and then
purified with the polyA Sepharose 4B column. After
separation with SDS-PAGE, the protein band corresponding
to p64 was cut from the gel for further analysis. These gel
pieces were collected and purified using the electro-elution
method (Model 422 Electro-Eluter, Bio-Rad). The protein
sample was transferred to a PVDF film through Prosorb and
washed with 1% TFA and H2O, and the film was then dried
at 40–60 -C. The N-terminal five amino acids were
analyzed using an ABI 491A protein sequencer (Procise,
Applied Biosystems).
RNA polymerase activity assays
The RdRp activity of the protein samples was examined
using the filter-binding polymerase assay modified from
that used in the polymerase activity assay of hepatitis C
virus (HCV) RdRp (Ronald et al., 1998; Yamashita et al.,
1998). Specifically, a total volume of 50 Al reaction
mixture was prepared that contains 50 mM Tris–HCl, pH
8.0, 7.5 mM KCl, 8 mM MgCl2, 10 mM DTT, 1% BSA,
3.5 AL of 1 mM UTP, 3.33 ACi of [a-32P] UTP
(Amersham Pharmacia), 3.125 Ag/ml polyA (Fluka),
1 Ag/ml oligoU16 (Takara), 20 units of RNAase inhibitor
(SABC), and 50 Ag/ml actinomycin D. The mixture was
incubated at 37 -C for 1 h and the reaction was stopped by
adding a cold buffer solution containing 20 mM sodium
pyrophosphate and 5% trichloroacetic acid. 30 Al of the
reaction solution was dotted on the GF/C glass microfibre
filters (Whatman) and washed with the cold buffer 5 times
and then with 75% ethanol once. The incorporated
triphosphate was assayed by measuring 32P using a liquid
scintillation counter (LS6000, Beckman). To evaluate
whether SARS-CoV RdRp has an RNA-dependent DNA
polymerase activity, a reverse transcriptase activity assay
was also carried out in which a polyrA/oligo(dT)12–18 was
used as template-primer and dTTP and [a-32P]TTP
(Amersham Pharmacia) were used as substrates, respec-
tively. MMLV RT (Promega) was used as a standard
reverse transcriptase for comparison.Acknowledgments
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